News from NYU Langone Health
Becker's Hospital Review
New York City-based NYU Langone Health reported an operating income of $482.8 million on $15.4 billion in revenue for the fiscal year ended 31 August 2025, maintaining a 3.1% operating margin. This represents a 9.6% increase in operating revenue from the prior year. According to Joseph Lhota, executive vice president, vice dean, CFO and chief of staff, this performance reflects contributions from 麻豆视频入口, which achieved a 7.5% operating margin, offset by an operating loss from the NYU Grossman Schools of Medicine. Expenses rose 9.6% to $14.9 billion, driven by salaries, pharmacy, and medical supply costs.
11/19/2025
The Bump
The article discusses the risks of consuming cannabis edibles during pregnancy. Meleen Chuang, MD, chief of Obstetrics and Gynecology at NYU Langone Hospital鈥擝rooklyn, explains that THC can cross the placenta and affect fetal development. She notes it may disrupt the brain and nervous system, potentially impacting learning and emotional control. Dr. Chuang also warns that the delayed effects of edibles increase the risk of accidental overdose and advises against any form of cannabis, including CBD, during pregnancy and breastfeeding.
11/19/2025
Crain's New York Business
Jinsy A. Andrews, MD, director, Amyotrophic Lateral Sclerosis (ALS) Center, NYU Langone Health, joins NYU Langone Health as director of its ALS Center and medical director of ALS clinical trials in the Department of Neurology, which aims at advancing treatments through research; providing comprehensive, integrated care to patients; and finding a cure for the debilitating disease.
3/28/2025
Archynewsy
A new analytical tool can improve a hospital's ability to limit the spread of antibiotic-resistant infections over customary methods like contact tracing, according to a study in Nature Communications. The method combines patient mobility data, clinical tests, health records, and genomic data to infer the presence of asymptomatic carriers. The research, which focused on carbapenem-resistant Klebsiella pneumoniae, was a collaborative effort that included Bo Shopsin, MD, PhD, associate professor in the Department of Medicine and the Department of Microbiology at NYU Grossman School of Medicine and director of Molecular Epidemiology, along with researchers from Columbia University and the University of California, San Francisco.
11/19/2025
OncLive
Benjamin Herzberg, MD, of Columbia University Medical Center, discussed the therapeutic challenges of aggressive non-small cell lung cancer (NSCLC) subtypes, explaining they are often 'immune cold' and respond poorly to standard treatments. For KEAP1-mutated tumors, which are highly stress-tolerant, he highlighted an investigator-initiated trial at NYU Langone's Cancer Center. This trial, which is evaluating glutamine-directed therapy, is being conducted by Salman R. Punakar, MD, assistant professor in the Department of Medicine at NYU Grossman School of Medicine. Herzberg also mentioned other novel strategies, underscoring the need for comprehensive genomic testing for all patients.
11/19/2025
Optometry Times
Colleen Dye, OD, a pediatric optometrist at NYU Langone Eye Center, clinical instructor, Department of Ophthalmology at NYU Grossman School of Medicine, shared her perspective on best practices in pediatric optometry. She emphasized proactive myopia management, including lifestyle factors like increased outdoor time, and the importance of early comprehensive eye exams. Dye also highlighted new developments, such as the FDA clearance of Essilor Stellest spectacle lenses and her team's participation in amblyopia treatment studies using VR headsets. She noted that her integrative approach at NYU Langone Health involves close collaboration with other specialists to ensure comprehensive, personalized care.
11/19/2025
Health
The Food and Drug Administration (FDA) is removing its black box warning on hormone replacement therapy (HRT) products containing estrogen or progestogen, which previously cited risks of cardiovascular disease, breast cancer, and dementia. According to Elizabeth Poynor, MD, gynecologic oncologist, and clinical professor at NYU Langone Medical Center, the FDA has realized that old data cannot be applied to new medications or different populations. She noted the original warning was a blanket cautionary label that had ramifications for decades. The article also discusses that HRT is not suitable for everyone and comes in various forms.
11/19/2025
Medscape
The TUXEDO-2 trial found that prasugrel may be preferable to ticagrelor for patients with diabetes undergoing percutaneous coronary intervention for multivessel disease. According to lead author Sripal Bangalore, MD, MHA, FAHA, professor of medicine at NYU Grossman School of Medicine and director of Cardiac Catheterization Laboratory, patients receiving prasugrel with aspirin had a lower rate of a composite of death, myocardial infarction, stroke, and major bleeding at one year compared to those on ticagrelor. Dr. Bangalore, who presented the results at the American Heart Association Scientific Sessions 2025, stated the findings indicate the two drugs are not interchangeable.
11/20/2025
Diagnostics World
Watchmaker Genomics has launched TAPS+, a next-generation technology that unites genetic and epigenetic readouts from the same DNA molecule. The technology is designed to advance applications in translational oncology, early cancer detection, and therapy response monitoring. Among the early evaluators was Matija Snuderl, MD, director of Molecular Pathology in the Department of Pathology at NYU Langone Health. He stated that TAPS+ allows for the direct detection of 5mC alongside genetic drivers from difficult samples, calling the multimodal insight a significant advance for precision oncology.
11/19/2025
Long Island Advance
NYU Langone Health hospitals have received their 11th consecutive 鈥淎鈥 grade for patient safety and quality from The Leapfrog Group. The 鈥淎鈥 rating applies to Tisch Hospital, Kimmel Pavilion, NYU Langone Hospital鈥擝rooklyn, and NYU Langone Hospital鈥擫ong Island. Additionally, NYU Langone Hospital鈥擲uffolk improved its grade from a 鈥淐鈥 to a 鈥淏鈥 eight months after its merger with the health system. Alec Kimmelman, MD, PhD, dean of NYU Grossman School of Medicine and chief executive officer of NYU Langone Health, stated that the organization's reputation is built on safe, top-quality care and praised the extraordinary pace of improvements.
11/20/2025
Baltimore Fishbowl
The Kennedy Krieger Institute received an $8.17 million grant from the National Institutes of Health to lead a 14-site Batten Disease Clinical Research Consortium aimed at advancing treatments for rare pediatric neurodegenerative disorders. NYU Langone Health is one of the participating sites in the new network, which will be headquartered at Kennedy Krieger鈥檚 Batten Disease Center of Excellence. The project, funded by several NIH institutes, will also launch a national Batten disease biorepository to provide a foundation for future advances in treatments for the disease.
11/19/2025
HERE New York
NYU Langone Health has relocated its BioLabs biotech incubator from Manhattan to a new, larger facility in Long Island City, Queens. The new location spans over 100,000 square feet, offering state-of-the-art laboratory and office spaces for emerging biotech startups. This strategic move is part of an initiative to enhance resources for early-stage companies and bolster New York City's life sciences ecosystem. The incubator provides members with shared equipment, business support, and acceleration programs to foster innovation and economic growth in the region.
11/20/2025
